MESO Q2 2021 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+13.6% YoY

Gross Profit

-$18M-825.2% margin

Operating Income

-$26M-1176.8% margin

Net Income

-$26M-1149.0% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

+73.5%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$687M

Total Liabilities

$169M

Stockholders' Equity

$519M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+13.6%
Gross Profit	-$18M	-$17M	-6.5%
Operating Income	-$26M	-$24M	-11.0%
Net Income	-$26M	-$25M	-4.5%